Abstract
This chapter emphasizes
-
That these excellent blood pressure-lowering agents have been proved in randomized clinical trials (RCTs) to decrease cardiovascular disease (CVD) outcomes in patients with hypertension but carry a significant risk for heart failure (HF) in the elderly and in blacks. This increased incidence of HF appears to be ignored by analysts of RCTs and is discussed in Chapter 8.
-
When to choose a calcium antagonist.
-
Which one to choose.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977;17:149.
Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982;307:1618.
Krikler DM, Harris L, Rowland E. Calcium-channel blockers and beta blockers: Advantages and disadvantages of combination therapy in chronic, stable angina pectoris. Am Heart J 1982;104:702.
Terry RW. Nifedipine therapy in angina pectoris: Evaluation of safety and side effects. Am Heart J 1982; 104:681.
Lette J, Gagnon RM, Lemire TG, et al. Rebound of vasospastic angina after cessation of long-term treatment with nifedipine. Can Med Assoc J 1984;130:1169.
Choong C YP, Roubin GS, Shen WF, et al. Effects of nifedipine on arterial oxygenation at rest and during exercise in patients with stable angina. J Am Coll Cardiol 1986;8:1461.
Ballester E, Roca J, Rodriquez-Roisin R, etal. Effectof nifedipine hypoxemia occurring after metacholine challenge in asthma. Thorax 1986;41:468.
Diamond JR, Cheung JT, Fang LST. Nifedipine-induced renal dysfunction: Alteration in renal hemodynamics. Am J Med 1984;77:905.
Bhatnagar SK, Amin MM, Al-Yusuf AR. Diabetogenic effects of nifedipine. BMJ 1984;289:19.
McKenney JM, Goodman RP, Wright JT Jr. Use of antihypertensive agents in patients with glucose intolerance. Clin Pharm 1985;4:649.
Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994;120:663–664.
Khan M Gabriel. Angina. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.
Farringer JA, Green JA, O’Rourke, et al. Nifedipine-induced alterations in serumquinidineconcentrations. Am Heart J 1984;108:1570.
VanLith RM, Appleby DH. Quinidine-nifedipine interaction. Drug Intell Clin Pharm 1985;19:829.
Verapamil in acute myocardial infarction: The Danish Study Group on Verapamil in Myocardial Infarction. Eur Heart J 1984;5:516.
Scheidt S, Frishman WF, Packer M, et al. Long term effectiveness of verapamil in stable and unstable angina pectoris: One year follow-up of patients treated in placebo-controlled, double-blind randomized clinical trial. Am J Cardiol 1982;50:1185.
Gulamhusein S, Ko P, Klein GJ. Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J 1983;106:145.
Zalman F, Perloff TK, Durant NN, et al. Acute respiratory failure following intravenous verapamil in Duchenne’s muscular dystrophy. Am Heart J 1983;105:510.
Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1989;319:385.
Goldstein RE, Boccuzzi ST, Cruess D, et al. Diltiazem increases late onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52.
Palat GK, Hooker E A, Morahed A. Secondary mania associated with diltiazem. ClinCardiol 1984;7:611.
Terwee PM, Rosman JB, Van Der Geest S. Acute renal failure due to diltiazem. Lancet 1984;2:1337.
Lee TH, Friedman PL, Goldman L, et al. Sinus arrest and hypotension with combined amiodarone-diltiazem therapy. Am Heart J 1985;109:163.
Kuhlmann J. Effects of nifedipine and diltiazem on plasma levels and renal excretions of beta-acetyldigoxin. Clin Pharmacol Ther 1985;37:150.
Singh S, Doherty J, Udhop V, et al. Amlodipine versus nadolol in patients with stable angina pectoris. Am Heart J 1989;118:1137.
Lorimer AR, Smedsrud T, Walker P, Tyler HM. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12(Suppl 7):S89.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755.
Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm: A controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619.
PRAISE: Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: For the Prospective Randomised Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107.
Staessen JA, Fagard R, Lutgarde T, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757.
Michels KB, Rosner B A, Manson JE, et al. Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: The Nurses’ Health Study. Circulation 1998;97:1540.
Califf RM, Kramer JM. What have we learned from the calcium channel blocker controversy? Circulation 1998;97:1529.
Cutler JA. Calcium-channel blockers for hypertension: Uncertainty continues. N Engl J Med 1998;338: 679.
Borhani NO, Mercury M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): A randomised controlled trial. JAMA 1996;276:785.
Estacio RO, Jeffers B W, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338:645.
Tatti P, Pahor M, Byington RP, et al. Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 1997;96(Suppl I):1–764.
Pahor M, Kritchevsky SB, Zuccla G, et al. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998;21:193.
Matterson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: A comparison of six hypertensive agents with placebo. N Engl J Med 1993;328:914.
Khan M Gabriel. Valvular heart disease. In: Heart Disease, Diagnosis and Therapy. Baltimore, Williams & Wilkins, 1996.
Subramanian B, Bowles MJ, Davies AB, Raftery EB. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol 1982;49:125.
Subramanian VB. Calcium Antagonists in Chronic Stable Angina Pectoris. Amsterdam, Excerpta Medica/ Elsevier, 1983, p 213.
Theroux P, Taeymans Y, Waters DD. Calcium antagonists: Clinical use in the treatment of angina. Drugs 1983;25:178.
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
(2007). Calcium Antagonists (Calcium Channel Blockers). In: Cardiac Drug Therapy. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-238-0_5
Download citation
DOI: https://doi.org/10.1007/978-1-59745-238-0_5
Publisher Name: Humana Press
Print ISBN: 978-1-58829-904-8
Online ISBN: 978-1-59745-238-0
eBook Packages: MedicineMedicine (R0)